2020-01-13Impact Announced First-Patient-In of its PARP inhibitor IMP4297 in Phase 3 Study
Impact Therapeutics announced the phase 3 study of its PARP inhibitor IMP4297 had the first patient dosed recently. This study is a randomized, placebo-controlled, double-blinded, multi-center, phase 3 clinical study in China to evaluate the efficacy and
2020-01-13Announcement: Dr. Chih-Yi Hsieh was appointed as Chief Medical Officer of Impact Therapeutics
Impact Therapeutics announced that Dr. Chih-Yi Hsieh was appointed as Senior Vice President and Chief Medical Officer, being responsible for global clinical strategy and development of its pipeline products.
2019-11-01Impact Announced First-Patient-In of its PARP inhibitor IMP4297 Pivotal Study
Impact Therapeutics announced the pivotal clinical study of its PARP inhibitor IMP4297 had the first patient dosed recently. IMP4297 is a new chemical entity targeting PARP developed by Impact.
2019-09-12Impact Selected to Present at 2019 BioCentury NewsMakers Conference
Impact Therapeutics Inc. (“Impact”) was selected to present at BioCentury NewsMakers Conference on September 6th, 2019 in New York City. Dr. Jun Bao
2019-01-04Announcement: Bao Jun was appointed as the President & CEO of IMPACT Therapeutics, Inc.
The appointment was effective on Oct.01, 2018. The appointment will help the development of IMPACT Therapeutics, Inc. in China as well as globally. This is a strategic step taken by the Company.
2018-08-03IMPACT Therapeutics Raises $30 Million In Series C Financing
NANJING, China, Aug. 3, 2018 /PRNewswire/ -- IMPACT Therapeutics, Inc. (IMPACT), a China-based clinical-stage biopharmaceutical company dedicated to the discovery and development of "best-in-class" medicine for the treatment of cancer and othe
2017-05-09IMPACT Received IMP4297 Chinese IND Approval
IMPACT Therapeutics, Inc.（(IMPACT) announced that CFDA granted approval to its IND application of IMP4297, a potential best-in-class PARP inhibitor, in January 2017. The company dosed the first patient in its Australian Phase I trial in February 2017 and
2016-02-18IMPACT Therapeutics is pleased to announce the closing of a round of VC financing.
In Dec. 2015 IMPACT Therapeutics, a company dedicated to discovery, development and commercialization of novel and “best-in-class” therapeutics to treat cancer and other life-threatening disease, announced the completion of around $10 million series B fi
2015-01-14IMPACT Therapeutics successfully completed A round of financing
IMPACT Therapeutics is pleased to announce the closing of a round of VC financing. The VC firms include，The Lilly Asia Ventures, Cenova Ventures and WuXi AppTec Ventures, who are among the best known venture firms in the biomedical sectors in China.
2011-12-20IMS reported Impact Therapeutics in its R&D FOCUS drug news
IMSDRUGNEWS has a two-page introduction of IMPACT Therapeutics and IMPACT’s three ongoing oncology programs, in the Dec.19th, 2011(Volume 20, No.51) issue of R&D FOCUS drugnews.